TransAlta schedules third-quarter 2026 results conference call
Bitget2026/10/05 21:11TransAlta schedules third-quarter 2026 results release for Nov. 3, 2026, before markets open. Conference call, webcast set for Nov. 3, 2026 at 10:00 a.m. ET (9:00 a.m. Alberta time): https://edge.media-server.com/mmc/p/zj3d6q2q. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TransAlta Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610051711PRIMZONEFULLFEED9839986) on October 05, 2026, and is solely responsible for the information contained therein.
- TransAlta schedules third-quarter 2026 results release for Nov. 3, 2026, before markets open.
- Conference call, webcast set for Nov. 3, 2026 at 10:00 a.m. ET (9:00 a.m. Alberta time): https://edge.media-server.com/mmc/p/zj3d6q2q.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ-Genmab shares hit a three-year high as blood cancer drug combination study results are released
October 6 - Genmab (GMAB.CO) shares rose about 8%, reaching a three-year high and leading the STOXX 600 index (.STOXX). Genmab and AbbVie ABBV.N announced on Monday (link) that their combination therapy for blood cancer reduced the risk of disease progression and death in a late-stage clinical trial. The two companies stated that, compared to R-CHOP regimen alone, the combination therapy reduced the risk of disease progression or death in newly diagnosed patients by 51%. Analysts at Jefferies described this result as "impressive". The brokerage added that the data "easily met the bar for success" and exceeded investor expectations of approximately 40%. TD Cowen stated that the data establishes the combination therapy as a potential new standard of care, with peak market potential expected to exceed $3 billion. (For convenience of non-English speakers, Reuters has automated this report into several other languages. Automated translations may contain errors or lack necessary context, and Reuters makes no guarantees as to their accuracy. The automated translation is provided for reader convenience, and Reuters bears no responsibility for any damages or losses resulting from use of the automated translation.)
Ethereum Price Prediction Eyes $3,500 Before $60K Macro Target
AI and Aerospace “Dual Engines” Launched! Goldman Sachs Targets SpaceX (SPCX.US) at $230
Goldman Sachs reiterated its “Buy” rating on SpaceX in its research report, raising the 12-month target price from $220 to $230, representing an upside potential of nearly 45% from last Friday’s closing price.
Crypto prices
More
